Johnson & Johnson (JNJ)
Johnson & Johnson: The Return Of The Dividend King
Johnson & Johnson is reiterated as a buy, driven by pipeline progress and recent valuation correction. Icotyde's early FDA approval and $8B peak sales potential could add 8% annual growth to JNJ's top line. Consensus projects JNJ EPS CAGR of 8.9% (2026–2030), with forward P/E compressing from 20.8x to 14.8x.
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Royalty Pharma and J&J partner to develop autoimmune treatment
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Procter & Gamble, Johnson & Johnson Among 9 Companies To Announce Dividend Increases In The First Half Of April
Procter & Gamble is set to announce its 70th consecutive year of dividend growth in April, joining an elite group of long-term dividend growers. I anticipate PG's dividend increase will be 3–5%, slightly below last year's 5% boost, yielding a forward yield of 3.05–3.11%. Investors were rewarded with 10%+ increases from 4 companies in March, including a 22% increase from insurance company Globe Life.
Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength
Johnson & Johnson shows relative strength with a bull flag breakout attempt, supported by key moving averages, signaling improving demand and potential upside toward higher Fibonacci extension targets.
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
JNJ's rapid pipeline progress and new drug approvals in 2025 set the stage for stronger growth impact from its expanding portfolio in 2026.
Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios
Johnson & Johnson demonstrates a robust historical dividend growth profile, highlighted by 63 years of consecutive hikes. JNJ has an AAA credit rating, adding safety for the dividend. Though there are clear risks, the solid fundamentals of this company and the decent growth prospects make it an attractive investment compared to the highly valued overall market.
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
Johnson & Johnson (JNJ) closed the most recent trading day at $239.93, moving +1.98% from the previous trading session.
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and legal risks.
Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
J&J Expands New Drug Portfolio With Icotyde's FDA Approval
J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.
